DOI: 10.1148/radiol.260517 ISSN: 0033-8419
Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma
Gary A. Ulaner, Russ A. Kuker, Benjamin Diamond, James Hoffman, Pooja Motwani, Ben Goldenson, Yaser Homsi, Gary Schiller, Beth Thomsen, Alanna Vossen, Dickran Kazandjian, C. Ola LandgrenIn participants with multiple myeloma, CD38-targeted zirconium 89 deferoxamine-daratumumab immuno-PET/CT helped detect active myeloma, even in some participants with no signs of disease at fluorine 18 fluorodeoxyglucose PET/CT.